SCHEMBL10699151

SCHEMBL10699151

CC(=O)OC1CCC(COC(=O)c2ccccc2)O1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
CHRNB2 P17787 1/20 0.46
CHRNA5 P30532 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA4 P43681 1/20 0.46
ALDH1A1 P00352 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
POLB P06746 1/20 0.41
PPM1B O75688 1/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30324499 1.00 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL30867002 1.00 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL19060080 1.00 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL18483496 1.00 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL24739169 0.91 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL13531183 0.91 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL20610905 0.91 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL22474965 0.91 NPC1 (0.48) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL22021925 0.86 NPC1 (0.50) NPC1CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL13552715 0.84 NPC1 (0.46) NPC1CHRNB2CHRNA5CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2691408-B1 SYNTHESIS OF 5-AZACYTIDINE CELGENE INT SÁRL (CH) 2017-06-28 EP disclosed
US-7598230-B2 For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2009-10-06 US disclosed
EP-0285884-A2 Process to produce 2', 3'-Dideoxynucleosides Bristol-Myers Squibb Company (US) 1988-10-12 EP disclosed